Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

B-006

Supelco

Butalbital solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sinônimo(s):

5-Allyl-5-isobutylbarbituric acid

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C11H16N2O3
Número CAS:
77-26-9
Peso molecular:
224.26
Número MDL:
MFCD00056089
Código UNSPSC:
41116107
ID de substância PubChem:
329773093
NACRES:
NA.24

grau

certified reference material

Formulário

liquid

Características

SNAP-N-SPIKE®, SNAP-N-SHOOT®

embalagem

ampule of 1 mL

fabricante/nome comercial

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

concentração

1.0 mg/mL in methanol

técnica(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicação(ões)

forensics and toxicology

Formato

single component solution

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O

InChI

1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)

chave InChI

UZVHFVZFNXBMQJ-UHFFFAOYSA-N

Informações sobre genes

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

Butalbital is a barbiturate often combined with other medications such as acetaminophen or aspirin for the treatment of pain or codeine for headaches. Trade names of several butalbital combinations include Axocet®, Bucet, and Bupap® with acetaminophen and Axotal with aspirin. This certified reference solution is suitable for GC/MS or LC/MS applications in forensic analysis, clinical toxicology or urine drug testing.

Informações legais

Axocet is a registered trademark of Fougera Pharmaceuticals Inc.
Bupap is a registered trademark of ECR Pharmaceuticals Co., Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Palavra indicadora

Danger

Declarações de precaução

P210 - P260 - P280 - P301 + P310 - P311

Classificações de perigo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Código de classe de armazenamento

3 - Flammable liquids

Classe de risco de água (WGK)

WGK 1

Ponto de fulgor (°F)

49.5 °F - closed cup

Ponto de fulgor (°C)

9.7 °C - closed cup

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Karla A Moore et al.
Forensic science international, 134(2-3), 120-122 (2003-07-10)
Zaleplon ("Sonata") is a pyrazolopyrimidine derivative approved for use in the United States for the treatment of insomnia. To date, there has been little data in the toxicological literature where zaleplon has been implicated as causing a fatal intoxication, either
Stewart J Tepper et al.
Cleveland Clinic journal of medicine, 77(4), 236-242 (2010-04-03)
When patients who have frequent, disabling migraines take medications to relieve their symptoms, they run the risk that the attacks will increase in frequency to daily or near-daily as a rebound effect comes into play. This pattern, called medication overuse
William B Young et al.
Current pain and headache reports, 6(2), 151-155 (2002-03-02)
In the United States analgesic-overuse headache is often caused by butalbital-containing analgesics. These agents can cause physical and psychological dependency, and dangerous withdrawal syndromes. Butalbital-containing analgesics have already been banned in several European countries. They are proven effective in tension-type
Richard G Wenzel et al.
Pharmacotherapy, 22(8), 1029-1035 (2002-08-14)
To evaluate the role of butalbital-containing products in the management of migraine. Qualitative systematic search using MEDLINE (January 1966-November 2001), review of the United States Headache Consortium's evidence-based guidelines for migraine treatment, and review of other pertinent literature. Over 28
Seymour Solomon
Current pain and headache reports, 6(2), 147-150 (2002-03-02)
Butalbital compounds are of proven efficacy in the treatment of tension headache. Decades of experience have established their value in the treatment of other mild-to-moderate headaches. Untold numbers of people rely on these medications as their drug of choice or
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica